A week to build, a year to be found
Kris Chase had been writing software for 25 years and working as a fractional CTO when he started looking for information about peptides — and noticed how hard it was to find. The tracking data people wanted did not have a great home yet, and the signals were everywhere: search interest in peptide terms was climbing in a hockey-stick curve, and the apps that existed mostly covered a single corner of the market. The GLP-1 drugs used for weight loss had dedicated tools. The dozens — maybe hundreds — of other peptides people were using had almost nothing.
That gap was the whole idea. Chase built PeptIQ as a personalised tracker for all things peptide-related, not just the one everyone else was building for: log every dose, track your vials, work out draw volume, see your upcoming schedule, and keep a record instead of relying on memory. Around the tracker he added the things a serious user needs — blood-work uploads, journaling, a drug-interaction checker, educational guides and an AI assistant.
He built the first version in a single week. An AI code generation tool did the accelerating, and the stack stayed lean by design: Expo, React Native, TypeScript, Supabase and RevenueCat. It was his first venture building an app for himself rather than for clients, and it was not some moonshot invention — dozens of apps already did the same thing in one form or another. He built it anyway, and launched in January 2026.
Six months of silence
For about six months after launch, the blog did nothing. Chase had decided early that search would be the growth engine, and he wrote educational articles aimed at the exact questions peptide users were typing into Google — with useful tools embedded directly in the articles, like a reconstitution calculator sitting inside the guides. The content was the product marketing: every article answered a real question and handed the reader a reason to open the app.
Nothing happened for six to seven months. Then the rankings arrived. Over the trailing twelve months, 590,000 people clicked through to the site from his articles, and Google Search Console showed 13.2 million impressions in the same period. Google now accounts for roughly 70% of his clicks and revenue — at zero marginal cost, with no paid ads and no influencer deals anywhere in the story.
The audience is part of why it worked. PeptIQ's target users are primarily 45 to 55 years old, a demographic less likely to rely solely on AI chat interfaces — and far more likely to find a thorough, well-ranked guide, use the calculator embedded in it, and pay for the tracker behind it. The content matched the customer: careful, specific, and built around the job they were already trying to do.
The dashboard
When Chase recorded the Starter Story episode about nine months after launch, he showed his RevenueCat dashboard on camera. It read 70 active trials, 1,413 active subscriptions and $22,081 in revenue over the last 28 days. Cumulative revenue for the year had crossed $115,000, and monthly recurring revenue stood at about $14,539 — roughly $14,000 to $15,000, depending on the week.
The pricing is blunt: a hard paywall at about $30 a month or $130 a year, with no free tier. That bluntness is deliberate. The subscription model is straightforward, the customers are people managing a real routine, and the app's 4.7-star rating on the App Store suggests the trade is working: pay, and the tracker does the remembering for you.
By November 2026 the app had grown beyond its first platform. What started as an iPhone app now runs on iOS, Android and the web, at app.peptiq.io, with the same tracker, the same calculators and the same guides behind it. The business is still a side project next to a full-time job — nine months in, it was doing over $14,000 a month on the side, with no ads, no influencer deals and no team.
Why it worked
Chase's story is a useful corrective to the idea that a crowded market means no room. Dozens of apps already tracked peptides when he started; he read that as proof of demand, not as a reason to stop. The move was to find the untapped sub-niche inside the crowded market — every peptide, not just the famous one — and to serve it with unusual thoroughness.
The second lesson is patience with a compounding channel. Six months of nothing is a long time to keep writing articles that nobody reads, and most founders would have declared SEO dead and moved on to paid acquisition. Chase kept writing, because the channel he had chosen compounds: every article is an asset that keeps ranking, and every ranking sends people who already want the product.
The third is that a small, specific product can be a real business. PeptIQ does one job for one kind of user, charges a clear price for it, and lets search bring the customers. There was no launch spike, no viral moment, no fundraising — just a week of building, a year of writing, and a tracker that now pays for itself many times over.
The playbook
- Validate with search trends first — Google Search Trends showed a hockey-stick curve for peptide terms before a line of code was written.
- Pick the sub-niche inside a crowded market — GLP-1 apps covered one peptide; hundreds of others had no dedicated tool. The sub-niche was the whole opportunity.
- Build the MVP fast with AI tools — An AI-assisted coding tool took the first version from idea to shippable in about a week.
- Plant SEO seeds early, then wait — Educational articles with useful tools embedded — a reconstitution calculator inside the guides — did the selling for a year.
- Charge a hard paywall from day one — $30 a month or $130 a year, no free tier. The price filtered for people who actually needed the tracker.